Abbonarsi

Does glyceryl nitrate prevent post-ERCP pancreatitis? A prospective, randomized, double-blind, placebo-controlled multicenter trial - 23/08/11

Doi : 10.1016/j.gie.2008.11.042 
Camilla Nøjgaard, MD , Mads Hornum, MD, Margarita Elkjaer, MD, Claes Hjalmarsson, MD, PhD, Laurent Heyries, MD, PhD, Truls Hauge, MD, PhD, Kåre Bakkevold, MD, PhD, Per Kragh Andersen, Dr Med, Peter Matzen, MD, Dr Med

European Post-ERCP Pancreatitis Preventing Study Group

Current affiliations: Department of Surgery (K.B.), Haugesund Hospital Haugesund, Division of Gastroenterology, Østfold County Hospital Fredrikstad (T.H.), Fredrikstad, Department of Gastroenterology, Ullevål University Hospital (T.H.), Oslo, Norway, Department of Internal Medicine M and Surgery D, Glostrup Hospital (M.H.), Glostrup, Department of Gastroenterological Surgery CTX, Rigshospitalet (M.H.), Department of Biostatistics, University of Copenhagen (P.K.A.), Copenhagen, Department of Internal Medicine F and Surgery D, Gentofte Hospital (M.E.), Gentofte, Department of Gastroenterology, Hvidovre Hospital (P.M., C.N.), Hvidovre, Denmark, Department of Surgery, Malmö University Hospital (C.H.), Malmö, Department of Surgery, Halmstad Hospital (C.H.), Halmstad, Sweden, Department of Gastroenterology, Conception Hospital (L.H.), Marseille, France 

Reprint requests: Camilla Nøjgaard, MD, Hvidovre Hospital, Kettegårds Alle 30, 2650 Hvidovre, Denmark.

Hvidovre, Glostrup, Gentofte, Copenhagen, Denmark, Malmö, Halmstad, Sweden, Marseille, France, Fredrikstad, Oslo, Haugesund, Norway

Abstract

Objective

Acute pancreatitis is the most dreaded complication of ERCP. Two studies have shown a significant effect of glyceryl nitrate (GN) in preventing post-ERCP pancreatitis (PEP). We wanted to evaluate this promising effect in a larger study with a realistically precalculated incidence of PEP.

Design/Patients

A randomized, double-blind, placebo-controlled multicenter study including patients from 14 European centers was performed. A total of 820 patients were entered; 806 were randomized.

Intervention

The active drug was transdermal GN (Discotrine/Minitran, 3M Pharma) 15 mg/24 hours; placebo (PL) was an identical-looking patch applied before ERCP. A total of 401 patients received GN; 405 received PL.

Results

Forty-seven patients had PEP (5.8%), 18 (4.5%) in the GN group and 29 (7.1%) in the PL group. The relative risk reduction of PEP in the GN group of 36% (95% CI, 11%-65%) compared with the PL group was not statistically significant (P = .11). Thirteen had mild pancreatitis (4 in the GN group, 9 in the PL group), 26 had moderate pancreatitis (9 in the GN group, 17 in the PL group), and 8 had severe pancreatitis (5 in the GN group, 3 in the PL group). Headache (P < .001) and hypotension (P = .006) were more common in the GN group. Significant variables predictive of PEP were not having biliary stones extracted; hypotension after ERCP; morphine, propofol, glucagon, and general anesthesia during the procedure; or no sufentanil during the procedure.

Conclusions

The trial showed no statistically significant preventive effect of GN on PEP. Because of a considerable risk of a type II error, an effect of GN may have been overlooked. (ClinicalTrials.gov ID: NCT00121901.)

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : GN, PEP, PL


Mappa


 DISCLOSURE: All authors disclosed no financial relationships relevant to this publication.
 The EPEPPS-group, contributors: Ulrich Bang, Department of Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark; Finn Møller Pedersen and Ove B Schaffalitzky de Muckadell, Department of Internal Medicine S, Odense University Hospital, Odense, Denmark; Taran Søberg, Division of Gastroenterology, Østfold County Hospital Fredrikstad, Fredrikstad, Norway; Lars Karlsen and Tom Glomsaker, Department of Internal Medicine and Surgery, Stavanger University Hospital, Stavanger, Norway; Peter Vilman, Department of Surgery D, Gentofte Hospital, Gentofte, Denmark; Trine Stigaard Larsen, Mikkel Westen, Svend Schulze, Department of Internal Medicine M and Surgery D, Glostrup Hospital, Glostrup, Denmark; Hans Kromann Andersen and Peter Vestergaard, Department of Gastroenterology and Surgery, Roskilde County Hospital Køge, Denmark; Mette Skov, Mark James McCullagh, Lars Bo Svendsen, Department of Gastroenterological Surgery CTX, Rigshospitalet, Copenhagen, Denmark; Nathalie Lesavre, Center of Clinical Investigation, North Hospital, Marseille, France; Marc Barthet, Department of Gastroenterology, North Hospital, Marseille, France; Per Almquist, Ervin Toth, Department of Surgery, Malmö University Hospital, Malmö, Sweden; Bengt Börjesson and Hans Högström, Department of Surgery, Halmstad Hospital, Halmstad, Sweden; José Sahel, Department of Gastroenterology, Conception Hospital, Marseille, France; Martin Theil Jensen, Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
 If you want to chat with an author of this article, you may contact her at mille@dadlnet.dk.


© 2009  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 69 - N° 6

P. e31-e37 - maggio 2009 Ritorno al numero
Articolo precedente Articolo precedente
  • Are bowel purgatives and prokinetics useful for small-bowel capsule endoscopy? A prospective randomized controlled study
  • Aymer Postgate, Paris Tekkis, Neil Patterson, Aine Fitzpatrick, Paul Bassett, Chris Fraser
| Articolo seguente Articolo seguente
  • Pilot study for in vivo cellular imaging of the muscularis propria and ex vivo molecular imaging of myenteric neurons (with video)
  • Kazuki Sumiyama, Hisao Tajiri, Fusao Kato, Taiko Imura, Kaori Ono, Keiichi Ikeda, Hiroo Imazu, Christopher J. Gostout

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.